Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Abstract 767 Tosedostat is a novel oral inhibitor of the M1/17 family of aminopeptidases which induces an amino acid deprivation response that is selectively toxic for myeloid blasts (Leuk Res. 2011: 5:677-81) and has shown promising activity in elderly relapsed/refractory AML patients (J Clin Oncol...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2011-11, Vol.118 (21), p.767-767
Main Authors: Cortes, Jorge E., Feldman, Eric J, Yee, Karen, Rizzieri, David A., Advani, Anjali S., Charman, Anthony, Toal, Martin J., Kantarjian, Hagop M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 767 Tosedostat is a novel oral inhibitor of the M1/17 family of aminopeptidases which induces an amino acid deprivation response that is selectively toxic for myeloid blasts (Leuk Res. 2011: 5:677-81) and has shown promising activity in elderly relapsed/refractory AML patients (J Clin Oncol 2010:28:4333-8). The OPAL study was undertaken to compare the activity of tosedostat at a once-daily dose of 120 mg for 24 weeks compared to 240 mg once daily for 8 weeks followed by 120 mg once daily for a further 16 weeks., as measured by bone marrow and hematology responses at 24 weeks. This was a phase II randomized (1:1) multi-center study. Patients were eligible if aged 60 years or older with previous CR lasting
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V118.21.767.767